Follow Us:
Oxyphenbutazone

Tandearil

Oxyphenbutazone

Oxyphenbutazone is a pyrazoline-based non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and mild uricosuric properties, structurally related to phenylbutazone

Dosage Form:
Dosage Strength:
CAS No.: 129-20-4
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Non-selective COX inhibitors
Class: Pyrazoline Derivatives

Uses of Oxyphenbutazone

Oxyphenbutazone was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Anti-inflammatory Activity: Some derivatives demonstrate activity against inflammatory pathways in experimental studies.
  • Analgesic Activity: Certain compounds have shown potential for reducing pain in pharmacological research.
  • Antimicrobial Activity: Selected derivatives have demonstrated antibacterial and antifungal properties in laboratory studies.
  • Antioxidant Activity: Some compounds have been studied for their ability to reduce oxidative stress.
  • Anticancer Research: Various pyrazoline compounds are being investigated for potential effects on cancer-cell growth and survival.
  • Other Pharmacological Research: Selected derivatives have also been studied for potential anticonvulsant, antidepressant and other biological activities.

Contraindication of Oxyphenbutazone

Oxyphenbutazone was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the active compound or its formulation ingredients.
  • Severe hepatic or renal impairment where the specific medicine is unsuitable.
  • Previous serious adverse reactions associated with the particular derivative.
  • Pregnancy or breastfeeding when the specific compound has established or suspected fetal or infant risks.
  • Certain blood disorders or other medical conditions where the compound's known toxicity makes its use inappropriate.

Precautions for Oxyphenbutazone

Oxyphenbutazone was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Allergic Reactions: Patients should be monitored for hypersensitivity reactions, including skin rashes, itching and swelling.
  • Liver and Kidney Function: Caution may be necessary in patients with hepatic or renal impairment, depending on the individual compound.
  • Gastrointestinal Effects: Some pharmacologically active derivatives may cause nausea, abdominal discomfort or other gastrointestinal disturbances.
  • Blood Disorders: Certain compounds may require monitoring for potential effects on blood-cell production.
  • Pregnancy and Breastfeeding: Safety information may be limited for investigational derivatives. Use should be based on the specific medicine's established safety information.
  • Long-term Use: Long-term safety should not be assumed from short-term experimental studies

Drug Interactions for Oxyphenbutazone

Potential drug interactions were historically documented when Oxyphenbutazone was prescribed alongside certain medications. These included:

  • Anticoagulants and Antiplatelet Drugs: Some derivatives may require additional monitoring if they affect bleeding risk.
  • Other Anti-inflammatory Medicines: Concurrent use with NSAIDs or corticosteroids may increase adverse-effect risks for compounds with similar pharmacological actions.
  • Hepatotoxic Medicines: Medicines that can affect liver function may require additional monitoring when used with compounds carrying hepatic safety concerns.
  • Nephrotoxic Medicines: Concurrent use with medicines that affect kidney function may increase renal safety concerns.
  • Antibiotics and Antifungals: Metabolic interactions may occur depending on the specific derivative and the interacting medicine.
  • Other Experimental or Investigational Drugs: Combining investigational compounds may introduce unpredictable interactions and adverse effects.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Oxyphenbutazone.

The Oxyphenbutazone is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Oxyphenbutazone.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Oxyphenbutazone, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Oxyphenbutazone Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Oxyphenbutazone

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Oxyphenbutazone Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Oxyphenbutazone, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Oxyphenbutazone

The export of Oxyphenbutazone from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Oxyphenbutazone Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Oxyphenbutazone specifications, certificates of analysis, and other supporting documents required for Oxyphenbutazone export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Oxyphenbutazone export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Oxyphenbutazone regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Oxyphenbutazone documentation, labelling, Oxyphenbutazone manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Oxyphenbutazone Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Oxyphenbutazone, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.